Sanjeev Luther is President and CEO of Ernexa Therapeutics and a member of the Board of Directors. Sanjeev is a seasoned pharmaceutical executive with over 30 years in leadership roles at organizations including Cornerstone Pharmaceuticals, Bristol Myers Squibb, Novartis, Bausch and Lomb, and GE Healthcare.
Ernexa Therapeutics is developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease. Its lead cell therapy product, ERNA-101, is being developed for the treatment of ovarian cancer.
Hope is a catalyst for scientific ambition. It encourages researchers, clinicians, investors, and innovators to pursue solutions where none currently exist. In oncology, many major breakthroughs begin with the belief that a better answer is possible.
Ovarian cancer urgently needs bold, transformative treatment approaches – not just small, incremental improvements. Synthetic, allogeneic iMSCs as tumor-targeting delivery vehicles are an example of how cell biology and engineering may unite and overcome longstanding oncology challenges.
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.